GILD Furnishes earnings results (Ex. 99.1)
Summary
Gilead Sciences, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, on February 10, 2026, via Exhibit 99.1 press release. The company reported a strong year, including the successful U.S. launch of Yeztugo and continued growth for key products. Management anticipates continued growth and new product launches in 2026. • Full Year 2025 Product Sales (excluding Veklury) increased 4% year-over-year to $28.0 billion. • Full Year 2025 Biktarvy Sales increased 7% year-over-year to $14.3 billion. • Total Fourth Quarter 2025 Revenues increased 5% to $7.9 billion compared to the same period in 2024.
Why It Matters
Investors should note the significant year-over-year growth in product sales, particularly Biktarvy, and the overall increase in total revenues for both the fourth quarter and full year 2025, as detailed in Exhibit 99.1. This indicates strong operational performance and positive momentum, with management anticipating continued growth and new product launches in 2026.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how GILD traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View GILD Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“On February 10, 2026 , Gilead Sciences, Inc., a Delaware corporation ("Gilead"), announced its financial results for the quarter and year ended December 31, 2025.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000882095
- Filing Date
- Tuesday, February 10, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive